Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz(University of Colorado Denver), R. Scott Wright(Pacific Heart Institute), Anders Olsson(Linköping University), John J.V. McMurray(University of Glasgow), Hardi Mundl(Roche (Switzerland)), Jochen Brumm(Roche (Switzerland)), Jean‐Claude Tardif(Montreal Heart Institute), Christie M. Ballantyne(Baylor College of Medicine), Stephen J. Nicholls(Australian Centre for Heart Health), Bernard Chaitman(Saint Louis University), David Kallend(Roche (Switzerland)), Lawrence A. Leiter(St. Michael's Hospital), Markus Abt(Roche (Switzerland)), Prediman K. Shah, Eran Leitersdorf(Hebrew University of Jerusalem), Ingar Holme(Oslo University Hospital), Philip J. Barter(The Heart Research Institute)
Cited by 2,034
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k